Mesenchymal Stem Cell Therapy in Multiple System Atrophy

• ClinicalTrials.gov Identifier: NCT02315027
• Recruitment Status: Active, not recruiting
• First Posted: December 11, 2014
• Last Update Posted: February 12, 2021
• Sponsor: Mayo Clinic
• Information provided by (Responsible Party): Wolfgang Singer, Mayo Clinic

Study Description

Brief Summary:

The purpose of this study is to determine whether mesenchymal stem cells (MSCs) can be safely delivered to the cerebrospinal fluid (CSF) of patients with multiple system atrophy (MSA). Funding Source - FDA OOPD.

Condition or disease	Intervention/treatment	Phase
MSA	Biological: autologous mesenchymal stem cells	Phase 1

Detailed Description:

The primary aim is to evaluate the safety and tolerability of intrathecal injection of autologous MSCs in a dose escalation study in patients with MSA. Safety secondary goals include to monitor changes in peripheral blood and in components of CSF, and monitor for any changes of nervous system structures using MRI. Efficacy secondary goals include evaluating potential efficacy by providing a number of studies and instruments that will detect changes in the course of the disease in terms of autonomic and neurologic symptoms and deficits.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 30 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Intrathecal Autologous Mesenchymal Stem Cell Therapy in Multiple System Atrophy (MSA) - Effect of Dose and Natural History
• Study Start Date: October 2012
• Estimated Primary Completion Date: August 2021
• Estimated Study Completion Date: August 2021

Arms and Interventions

Arm

Intervention/treatment

Experimental: autologous mesenchymal stem cells; Administration of autologous mesenchymal stem cells

Biological: autologous mesenchymal stem cells; There will be three treatment groups of up to 8 patients each. Groups 1 will receive a single dose of cells. Groups 2 and 3 will receive 2 doses of cells separated by one month. Intrathecal injections into new subjects will be timed so that there is a minimum of one week between subject injections. The cell dose per group is as follows: Group 1: single intrathecal dose of 1 x 107 cells.; Group 2: one intrathecal dose of 5 x 107 cells followed one month (+/- 4 days) later by a second intrathecal dose of 5 x 107 cells.; Group 3: one intrathecal dose of 1 x 108 cells followed one month (+/- 4 days) later by a second intrathecal dose of 1 x 108 cells.

Outcome Measures

Primary Outcome Measures :

1. Adverse event frequency (by severity, type, attribution, and intervention dose). [ Time Frame: 14 months ]

Secondary Outcome Measures :

1. Rate of change of Unified Multiple System Atrophy Rating Scale (UMSARS) I score from baseline to 12 months (or last available date), compared with placebo limb of Rifampicin trial (historical control cohort). [ Time Frame: 12 months ]
2. Rate of change from baseline to 12 months (or last available date) in UMSARS II score. [ Time Frame: 12 months ]
3. Rate of change from baseline to 12 months (or last available date) in UMSARS total score. [ Time Frame: 12 months ]
4. Rate of change in COMPASS-select score from baseline to 12 months. [ Time Frame: 12 months ]
5. Change in CASS score and thermoregulatory sweat test (TST) % from baseline to 12 months. [ Time Frame: 12 months ]
6. MRI morphometric changes using dedicated algorithms to evaluate rate of atrophy of defined areas of brain from baseline to 12 months. [ Time Frame: 12 months ]
7. Change in CSF biomarkers from baseline to 2 months. [ Time Frame: 2 months ]

Eligibility Criteria

• Ages Eligible for Study: 30 Years to 80 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria

1. Participants aged 30-80 years old with a diagnosis of MSA based on clinical criteria and standardized autonomic testing. This approach allows for identification of patients with MSA with very high specificity and is yet sensitive enough to allow for enrollment of patients at a disease stage at which an intervention on the natural disease course has a meaningful impact on patient outcome. Patients therefore have to fulfill Gilman Criteria (2000) for probable MSA of the parkinsonian subtype (MSA-P) or cerebellar subtype (MSA-C) and have findings on autonomic function testing suggestive of MSA (CASS ≥5 or a TST% ≥25%).
2. Participants who are less than 4 years from the time of documented MSA diagnosis.
3. Participants with an anticipated survival of at least 3 years in the opinion of the investigator.
4. Participants who are willing and able to give informed consent.
5. "Normal" cognition as assessed by Mini-Mental State Examination (MMSE). We will require a value >24.

Exclusion Criteria

Any of the following conditions will exclude the participant from entering the study:

1. Women of childbearing potential who do not practice an acceptable method of birth control. Acceptable methods of birth control in this study are: surgical sterilization, intrauterine devices, partner's vasectomy, a double-protection method (condom or diaphragm with spermicide), hormonal contraceptive drug (i.e., oral contraceptive, contraceptive patch, long-acting injectable contraceptive) with a required second mode of contraception.
2. Participants with a clinically significant or unstable medical or surgical condition that, in the opinion of the investigator, might preclude safe completion of the study or might affect the results of the study. These include conditions causing significant central nervous system (CNS) or autonomic dysfunction, including congestive heart failure, recent (<6 months) myocardial infarct, cardiopulmonary disease, severe, uncontrolled hypertension, thrombocytopenia (<50 x 10(9)/L), severe anemia (<8g/dl), immunocompromised state, liver or kidney disease (creatinine >2.3mg/dl), uncontrolled diabetes mellitus (HbA1c >10g%), alcoholism, amyloidosis, uncontrolled hypothyroidism, sympathectomy, unstable peripheral neuropathies, concurrent infections, orthopedic problems that compromise mobility and activity of daily living, cerebrovascular accidents, neurotoxin or neuroactive drug exposure, parkinsonism due to drugs (including neuroleptics, alpha-methyldopa, reserpine, metoclopramide).
3. Participants with malignant neoplasms.
4. Participants who have taken any investigational products within 60 days prior to baseline.
5. Medications that could affect autonomic function. If patients are taking those medications, those will be suspended prior to autonomic testing. Therapy with midodrine, anticholinergic, alpha and beta adrenergic antagonists or other medications that affect autonomic function will be withdrawn 48 hours prior to autonomic evaluations. Fludrocortisone doses up to 0.2 mg per day will be permitted.
6. Diseases with features of Parkinsons Disease; e.g., diffuse Lewy body disease, progressive supranuclear palsy, essential tremor, hereditary olivopontocerebellar atrophy, or postencephalitic parkinsonism.
7. Dementia (DSM-IV criteria - American Psychiatric Association 1994). The score on the Mini-Mental State Examination must be >24.
8. History of electroconvulsive therapy.
9. History of brain surgery for Parkinsons disease.
10. Patients with contraindication for MRI scanning, including those with MRI-incompatible pacemakers
11. Patients with active systemic infection or local infection, which is close to the spinal injection site

Contacts and Locations

Locations

United States, Minnesota

Mayo Clinic in Rochester

Rochester, Minnesota, United States, 55905

Sponsors and Collaborators

Mayo Clinic

Investigators

• Principal Investigator: Wolfgang Singer, MD; Mayo Clinic
• Principal Investigator: Phillip Low, MD; Mayo Clinic

More Information

Additional Information:

Mayo Clinic Clinical Trials 

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Camilleri ET, Gustafson MP, Dudakovic A, Riester SM, Garces CG, Paradise CR, Takai H, Karperien M, Cool S, Sampen HJ, Larson AN, Qu W, Smith J, Dietz AB, van Wijnen AJ. Identification and validation of multiple cell surface markers of clinical-grade adipose-derived mesenchymal stromal cells as novel release criteria for good manufacturing practice-compliant production. Stem Cell Res Ther. 2016 Aug 11;7(1):107. doi: 10.1186/s13287-016-0370-8.

• Responsible Party: Wolfgang Singer, Associate Professor, Mayo Clinic
• ClinicalTrials.gov Identifier: NCT02315027
• Other Study ID Numbers: 12-005950; G4789 ( Other Grant/Funding Number: FDA - OOPD )
• First Posted: December 11, 2014
• Last Update Posted: February 12, 2021
• Last Verified: February 2021

Additional relevant MeSH terms:

Multiple System Atrophy; Shy-Drager Syndrome; Atrophy; Pathological Conditions, Anatomical; Primary Dysautonomias; Autonomic Nervous System Diseases; Nervous System Diseases; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Movement Disorders; Neurodegenerative Diseases; Hypotension; Vascular Diseases; Cardiovascular Diseases